GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Visgeneer Inc (ROCO:4197) » Definitions » Debt-to-Equity

Visgeneer (ROCO:4197) Debt-to-Equity : 0.75 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Visgeneer Debt-to-Equity?

Visgeneer's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$44.4 Mil. Visgeneer's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$114.2 Mil. Visgeneer's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$211.6 Mil. Visgeneer's debt to equity for the quarter that ended in Dec. 2023 was 0.75.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Visgeneer's Debt-to-Equity or its related term are showing as below:

ROCO:4197' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09   Med: 0.79   Max: 1.06
Current: 0.75

During the past 13 years, the highest Debt-to-Equity Ratio of Visgeneer was 1.06. The lowest was 0.09. And the median was 0.79.

ROCO:4197's Debt-to-Equity is ranked worse than
82% of 1072 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:4197: 0.75

Visgeneer Debt-to-Equity Historical Data

The historical data trend for Visgeneer's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Visgeneer Debt-to-Equity Chart

Visgeneer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.06 0.97 0.83 1.00 0.75

Visgeneer Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.78 1.00 0.72 0.75

Competitive Comparison of Visgeneer's Debt-to-Equity

For the Biotechnology subindustry, Visgeneer's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Visgeneer's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Visgeneer's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Visgeneer's Debt-to-Equity falls into.



Visgeneer Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Visgeneer's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Visgeneer's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Visgeneer  (ROCO:4197) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Visgeneer Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Visgeneer's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Visgeneer (ROCO:4197) Business Description

Traded in Other Exchanges
N/A
Address
Number 335, Sec. 6, Zhonghua Road, Xiangshan District, Hsinchu, TWN, 30094
Visgeneer Inc is a Taiwan based Biotech company involved in developing and, manufacturing biomedical products in the areas of Bacterial Fermentation, Medical Device, Cosmetics/Skin Care, and Cancer Gene identification. Its products include Blood Glucose and Ketone Monitoring System, Ginkgo Biloba series, Peptide-Complex series, Hyaluronic Acid Essence Series and High-Quality Masks among others.

Visgeneer (ROCO:4197) Headlines

No Headlines